HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.

AbstractBACKGROUND:
A model was built that characterized effects of individual factors on five-year prostate cancer (PCa) risk in the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCO) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). This model was validated in a third San Antonio Biomarkers of Risk (SABOR) screening cohort.
METHODS:
A prediction model for 1- to 5-year risk of developing PCa and Gleason > 7 PCa (HG PCa) was built on PLCO and SELECT using the Cox proportional hazards model adjusting for patient baseline characteristics. Random forests and neural networks were compared to Cox proportional hazard survival models, using the trial datasets for model building and the SABOR cohort for model evaluation. The most accurate prediction model is included in an online calculator.
RESULTS:
The respective rates of PCa were 8.9%, 7.2%, and 11.1% in PLCO (n = 31,495), SELECT (n = 35,507), and SABOR (n = 1790) over median follow-up of 11.7, 8.1 and 9.0 years. The Cox model showed higher prostate-specific antigen (PSA), BMI and age, and African American race to be associated with PCa and HGPCa. Five-year risk predictions from the combined SELECT and PLCO model effectively discriminated risk in the SABOR cohort with C-index 0.76 (95% CI [0.72, 0.79]) for PCa, and 0.74 (95% CI [0.65,0.83]) for HGPCa.
CONCLUSIONS:
A 1- to 5-year PCa risk prediction model developed from PLCO and SELECT was validated with SABOR and implemented online. This model can individualize and inform shared screening decisions.
AuthorsJonathan A Gelfond, Brian Hernandez, Martin Goros, Joseph G Ibrahim, Ming-Hui Chen, Wei Sun, Robin J Leach, Michael W Kattan, Ian M Thompson, Donna Pauler Ankerst, Michael Liss
JournalBMC urology (BMC Urol) Vol. 22 Issue 1 Pg. 45 (Mar 26 2022) ISSN: 1471-2490 [Electronic] England
PMID35351104 (Publication Type: Journal Article)
Copyright© 2022. The Author(s).
Topics
  • Cohort Studies
  • Early Detection of Cancer
  • Humans
  • Male
  • Proportional Hazards Models
  • Prostate
  • Prostatic Neoplasms (diagnosis, epidemiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: